H.-M. Reinold

Treatment Intensification with r-metHuG-CSF in High-Grade Malignant Non-Hodgkin’s Lymphomas

B. Steinke, A. Münz, C. Manegold, Mathias Freund et autres

Background: Hematologic growth factors may allow dose intensification of chemotherapy, possibly leading to improved treatment results in high-grade malignant non-Hodgkin’s lymphomas. In the present study, the feasibility of reducing the time intervals between treatment cycles of chemotherapy was examined. Patients and Methods: …

de (code pays fourni par la source)

Briefe an die Herausgeber – Letters to the Editors

M. Hünerbein, A. Münz, E. Späth‐Schwalbe, O. Prümmer et autres

Inhalt, Vol. 17, No. 3, 1994

M. Hünerbein, A. Münz, E. Späth‐Schwalbe, O. Prümmer et autres

Impressum, Vol. 17, No. 3, 1994

M. Hünerbein, A. Münz, E. Späth‐Schwalbe, O. Prümmer et autres

Hinweise für Autoren – Instructions to Authors

M. Hünerbein, A. Münz, E. Späth‐Schwalbe, O. Prümmer et autres

Industrieforum – Industrial Forum

M. Hünerbein, A. Münz, E. Späth‐Schwalbe, O. Prümmer et autres

Buchbesprechung – Book Review

M. Hünerbein, A. Münz, E. Späth‐Schwalbe, O. Prümmer et autres

AIO Mitteilungen

E. Holler, St. Thierfelder, Uta Behrends, L. Daum et autres

G-CSF for Treatment Intensification in High-Grade Malignant Non-Hodgkin’s Lymphomas

B. Steinke, C. Manegold, Mathias Freund, H.-M. Reinold et autres

Background: Hematologic growth factors may allow those intensification of chemotherapy possibly leading to an improvement of treatment results in high grade malignant non-Hodgkin’s lymphomas. In the present study the possibility of reducing the time intervals between treatment cycles of chemotherapy was examined. …

de (code pays fourni par la source)

Impressum, Vol. 15, No. 1, 1992

E. Holler, St. Thierfelder, Uta Behrends, L. Daum et autres

K rcbsgesellschaft -K rebsliga u n te r F o rtfü h ru n g d e r « Ö ste rreic h isch e n Z e itu n g fü r O nkologie» S chriftleitung W issenschaftlicher B eirat H …

Industrieforum – Industrial Forum

E. Holler, St. Thierfelder, Uta Behrends, L. Daum et autres

Sequentiell alternierende Chemotherapie bei hochmalignen Non-Hodgkin-Lymphomen mit VIM-Bleo und CHOP

B. Steinke, Andrea Kraft, H.-M. Reinold, Manfred Heim et autres

54 patients with high grade malignant NHL (stage II 19, stage III 10, stage IV 25 patients, medium age 56 years) were treated in an ongoing study with the VIM-Bleo/CHOP-regimen: Etoposide 100 mg/m2 i.v. days 1-3, Ifosfamide 1.5 g/m2 i.v. days 1-5 …

de (code pays fourni par la source)